Volume Status and Diuretic Therapy in Systolic Heart Failure, and the Detection of Early Abnormalities in Renal and Tubular Function Kevin Damman, Marie.

Slides:



Advertisements
Similar presentations
Admission B-Type Natriuretic Peptide Levels and In-Hospital Mortality in Acute Decompensated Heart Failure Fonarow GC et al. J Am Coll Cardiol 2007; 49(19):
Advertisements

Chronic Kidney Disease Manju Sood GPST3. What is CKD? Chronic renal failure is the progressive loss of nephrons resulting in permanent compromise of renal.
Horng H Chen MD on behalf of the NHLBI Heart Failure Clinical Research Network Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF):
Perioperative Management of Heart Failure Gamal Fouad S Zaki, MD Professor of Anesthesiology Ain Shams University
Mechanisms and Management in Acute Kidney Injury Paul Stevens Kent Kidney Care Centre.
The PREVEND Study: Screening for micro-albuminuria
Impact of Preoperative Renal Dysfunction in Patients Undergoing Off- pump vs On-pump Coronary Artery Bypass.
Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy.
CKD In Primary Care Dr Mohammed Javid.
A retrospective cohort study of Childhood post-streptococcal glomerulonephritis as a risk factor for chronic renal disease in later life Andrew V White,
Heart Failure with Normal Systolic Function: Better or Worse Prognosis? Maria Rosa Costanzo, M.D., F.A.C.C, F.A.H.A. Medical Director, Midwest Heart Specialists.
HYPERTENSION in ADPKD Sabine Karam M.D.. Introduction  ADPKD is the most common life-threatening single-gene disease  It affects over 12 million people.
Renal biopsy case Niels Marcussen Odense University Hospital Denmark.
S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Heart rate reduction with ivabradine and health related quality of life in.
analysis from the SHIFT study
Lesley Stevens MD Tufts-New England Medical Center
Congestive Heart Failure Stephen Gottlieb, MD Professor of Medicine Director, Cardiomyopathy and Pulmonary Hypertension University of Maryland.
Loop diuretics VS venous ultrafiltration in cardio-renal syndrome Radek Debiec SHO Renal Medicine LGH Sept 2013.
Early Detection and Prevention of Renal Failure Linda Fried, MD, MPH.
May 23rd, 2012 Hot topics from the Heart Failure Congress in Belgrade.
Biomarkers in the Cardiorenal Syndromes
CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.
Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Systolic.
Effect of ivabradine on recurrent hospitalization for worsening heart failure: findings from SHIFT S ystolic H eart failure treatment with the I f inhibitor.
DECREASING SLEEP-TIME BLOOD PRESSURE DETERMINED BY AMBULATORY MONITORING REDUCES CARDIOVASCULAR RISK Ramón C. Hermida, PhD; Diana E. Ayala, MD, MPH, PhD;
Association between Systolic Blood Pressure and Congestive Heart Failure in Hypertensive Patients Mrs. Sutheera Intajarurnsan Doctor of Public Health Student.
Dose Adjustment in Renal and Hepatic Disease
Blood Pressure Lability During Cardiac Surgery Is Associated With Adverse Outcomes Solomon Aronson, Edwin G. Avery, Cornelius Dyke, Joseph Varon, Jerrold.
0902CZR01NL537SS0901 RENAAL Altering the Course of Renal Disease in Hypertensive Patients with Type 2 Diabetes and Nephropathy with the A II Antagonist.
Stage 4 CKD presentation in patients over 75 Years Old differs from that in patients less than 75 Years of Age Hiromichi Suzuki, Tsutomu Inoue,Tomohiro.
Investigations: Urine examination. Urine examination. Serum K. Serum K. Serum creatinine. Serum creatinine. Blood Sugar. Blood Sugar. Hb. Hb.
Red Cell Distribution Width (RDW) as a Novel Prognostic Marker in Heart Failure: Data from the CHARM Program and the Duke Databank.
Dick de Zeeuw Department of Clinical Pharmacology University Medical Center Groningen The Netherlands Albuminuria; a tool for measuring non-blood pressure.
Case Report and Lit Review: Reduction of Proteinuria in Diabetic Nephropathy with Spironolactone Harry W. Floyd, M.D. Family Medicine Kingstree, South.
Occluded Artery Trial (OAT) Presented at The American Heart Association Scientific Session 2006 Presented by Dr. Judith S. Hochman OAT Trial.
The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT Systolic Heart failure.
Acute Heart Failure in Apical Ballooning Syndrome (Takotsubo/Stress Cardiomyopathy) Clinical Correlates and Mayo Clinic Risk Score Malini Madhavan, MBBS;
Kimberly Dunbar, PA-S2 Follow-up of Cardiovascular Risk Markers in Hypertensive Patients Treated with Irbesartan: Results of the i-SEARCH Plus Registry.
Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure Systolic Heart.
ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)
Heart rate in heart failure: Heart rate in heart failure: risk marker or risk factor? A subanalysis of the SHIFT trial on behalf of the Investigators M.
Embargoed Until 3:45 p.m. ET, Sunday, Nov. 8, 2015
6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.
Early Eplerenone Treatment in Patients with Acute ST-elevation Myocardial Infarction without Heart Failure REMINDER* Gilles Montalescot, Bertram Pitt,
TREATMENT OF ANEMIA WITH DARBEPOETIN ALFA IN SYSTOLIC HEART FAILURE Karl Swedberg, M.D., Ph.D., James B. Young, M.D., Inder S. Anand, M.D., Sunfa Cheng,
Regional Differences in Heart Failure Medication Changes During Acute Heart Failure Hospitalization: Findings From the PROTECT Trial Robert J. Mentz, Gad.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
The SYMPHONY Trial Reference Reddan DN, et al. Renal function, concomitant medication use and outcomes following acute coronary syndromes. Nephrol Dial.
The CHART-2 Study (The Chronic Heart Failure Analysis and Registry in the Tohoku District 2) Source Shiba N, Nochioka K, Miura M, et al. Trend of westernization.
Date of download: 7/3/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Fibroblast Growth Factor 23 and Risks of Mortality.
Cardiovascular Disease and Antihypertensives The RENAAL Trial Reference Brunner BM, and the RENAAL study group. Effects of losartan on renal and cardiovascular.
신장내과 R4 강혜란 Cardiorenal syndrome (CRS).  Patients with heart failure (HF) who have a reduced GFR -> Mortality ↑  Patients with chronic kidney disease.
  Aldosterone Targeted NeuroHormonal CombinEd with Natriuresis TherApy – Heart Failure Trial ATHENA-HF Trial Javed Butler, M.D., M.P.H, M.B.A. On behalf.
Total Occlusion Study of Canada (TOSCA-2) Trial
Aldosterone Targeted NeuroHormonal CombinEd with Natriuresis TherApy – Heart Failure Trial ATHENA-HF Trial Javed Butler, Marvin A. Konstam, G. Michael.
Nephrology Journal Club The SPRINT Trial Parker Gregg
The LIVES Sub-analysis
Angiotensin converting enzyme inhibitors / angiotensin receptor blockers and contrast induced nephropathy in patients receiving cardiac catheterization:
DIAGNOSIS No symptoms = no heart failure. DIAGNOSIS No symptoms = no heart failure.
David M Kaye MD, PhD on behalf of the REDUCE LAP HF Investigators
E. Martinelli DVM; P. Brambilla DVM, PhD; C. Locatelli DVM, PhD; S
Plasma kidney injury molecule-1 in heart failure: renal mechanisms and clinical outcome Johanna E. Emmens, BSc, Jozine M. ter Maaten, MD, Yuya Matsue,
The percentage of subjects with de novo development of renal function impairment (GFR
Furosemide-Induced Severe Hypocalcemia in Latent Hypoparathyroidism
Systolic Heart failure treatment with the If inhibitor ivabradine Trial The effect of heart rate reduction with ivabradine on renal function in patients.
Volume 89, Issue 6, Pages (June 2016)
Division of Cardiovascular Diseases No relevant author disclosures
Systolic Heart failure treatment with the If inhibitor ivabradine Trial Effect of ivabradine on recurrent hospitalization for worsening heart failure:
Receiver-operating characteristics analyses for predicting AKI progression or AKI progression with death. Receiver-operating characteristics analyses for.
Presentation transcript:

Volume Status and Diuretic Therapy in Systolic Heart Failure, and the Detection of Early Abnormalities in Renal and Tubular Function Kevin Damman, Marie J. Ng Kam Chuen, Robert J. MacFadyen, Gregory YH Lip, David Gaze, Paul O. Collinson, Hans L. Hillege, Wim van Oeveren, Adriaan A. Voors, and Dirk J. van Veldhuisen University Medical Center Groningen, Groningen, The Netherlands University of Birmingham, Birmingham, United Kingdom St George’s Hospital, London, United Kingdom

Background  Renal failure is prevalent in acute and chronic heart failure  Renal failure is the most important predictor of outcome in patients with heart failure  Pathophysiology of reduced glomerular filtration rate (GFR):  Decreased renal blood flow (RBF)  Increaed central venous pressure (CVP) J Am Coll Cardiol 2011;57:

Background Especially in situations of reduced RBF, increased CVP is associated with reduced GFR Damman et al. Eur J Heart Fail 2007

Background  Higher CVP associated with lower eGFR along the whole spectrum of cardiovascular disease  CVP predicts worsening renal function (WRF) Damman et al. JACC 2009, Mullens et al. JACC 2009

Background  Diuretics are the cornerstone of treatment of symptoms and signs of congestion in heart failure.  However, the efficacy of diuretics to decrease morbidity and mortality in heart failure has never been established.  Higher doses of diuretics have been associated with worsening renal function J Am Coll Cardiol 2011;57:

Background Metra et al. Eur J Heart Fail 2008 High dose of IV diuretics associated with occurence of WRF

Background Felker et al. NEJM 2011 High dose of IV diuretics associated with occurence of WRF WRF occurred significantly more in high vs low dose Diuretic regime: 23 vs 14%, P = 0.04 DOSE study

Worsening renal function, at any point in time, is associated with poor prognosis Background Damman et al. Eur J Heart Fail Damman et al. J Card Fail 2007

Background Tubular Damage is prevalent in Heart Failure Damman et al. Heart 2010

Summary  Higher central venous pressure associated with impaired GFR, tubular damage and poor outcome  Diuretics improve QoL and congestion, but may be associated with WRF and worse outcome J Am Coll Cardiol 2011;57:

Summary Diuretic therapy Worsening renal function Diuretic therapy Improving Congestion Prognosis J Am Coll Cardiol 2011;57:

Aim and Hypothesis  Aim:  To investigate the effect modulation of congestion by diuretics (witdrawal and re-initiation) on markers of renal and tubular function in heart failure.  Hypothesis:  Diuretic therapy reduces central and renal venous pressure, improving GFR and tubulo-interstitial damage J Am Coll Cardiol 2011;57:

Methods Prospective cohort, Birmingham, UK  Patient population (N = 30):  chronic systolic heart failure (EF < 40%)  presumed euvolemic state  on oral loop diuretic regimen (Furosemide 40 / 80 mg )  treated according to guidelines J Am Coll Cardiol 2011;57:

Methods 7 day Study Protocol BaselineDiuretic withdrawalDiuretic resumption Day 1 Tue 2 Wed 3 Thurs 4 Fri 5 Sat 6 Sun 7 Mon Usual dose of furosemide X 50 mg IV furosemide XXX Blood and urine biomarkers 0, 4, 8 hXX X J Am Coll Cardiol 2011;57:

Methods  Outcome measures: - Markers of Volume overload: ANP, BNP - Markers of glomerular filtration: serum creatinine - Markers of tubulo-interstitial damage (urine): - KIM-1 (Kidney Injury Molecule 1) - NAG (N-acetyl-beta-D-glucosaminidase) - NGAL (Neutrophil Gelatinase Associated Lipocalin) J Am Coll Cardiol 2011;57:

Variable Value Age 70  7 Gender (N male (%))26 (87) BMI (Kg/m 2 ) 26  6 SBP (mmHg) 136  22 DBP (mmHg) 77  12 LVEF (%) 25  8 NYHA class (I, II, III (%))3 / 87 / 10 Etiology of Heart failure (%) Coronary Artery Disease67 Hypertension3 Idiopathic17 Other13 Baseline Characteristics J Am Coll Cardiol 2011;57:

Baseline Characteristics Variable Value Serum creatinine (mg/dL)1.3 (1.0 – 1.6) eGFR (mL/min/1.73m 2 )44 ( ) Hemoglobin (g/dL) 9.1  1.2 BNP (pg/mL)154 ( ) ANP (pg/mL)794 (264 – 2543) Medication ACE-inhibitor (n (%))20 (67) ARB (n (%))10 (33) Beta-Blocker (n (%))23 (77) Lipid lowering (n (%))23 (77) Furosemide (n (%))30 (100) Furosemide 40 mg (n (%))20 (67) Furosemide 80 mg (n (%))10 (33) Spironolacton (n (%))10 (33) J Am Coll Cardiol 2011;57:

Results VariableBaseline uKIM-1 (ng/gCr)562 (99 – 1379) uNAG (U/gCr)8.5 (5.7 – 14.0) uNGAL (µg/gCr)25 (0 – 26) sNGAL (ng/mL)470 (330 – 601) J Am Coll Cardiol 2011;57:

Results: Creatinine Mean ± SEMs are presented * P < vs Day 1, baseline, † P < 0.05 vs Day 4 J Am Coll Cardiol 2011;57:

Results: ANP/BNP Day 1 Baseline Day 1, 8 hours Day 2Day 3Day 4Day 7 ANP (pg/mL) 794 (264 – 2543) 898* (358 – 2665) 937* (347 – 2748) 879* (384 – 2845) 880* (343 – 2704) 1183* (421 – 2794) BNP (pg/mL) 157 (104 – 92) 166 (96 – 283) 143 (66 – 218) 152 (96 – 290) 221† (102 – 350) 149# (70 – 346) * P < 0.01 vs baseline, † P < 0.05 vs baseline, # P < 0.05 vs Day 4 Diuretic withdrawal and reinitiation J Am Coll Cardiol 2011;57:

Results: ANP/BNP Mean ± SEMs are presented. * P < 0.01 vs Day 1, baseline, † P < 0.05 vs Day 1, # P < 0.05 vs Day 4 J Am Coll Cardiol 2011;57:

Results: Tubular markers Diuretic withdrawal Median and IQRs are presented. * P < 0.01, † P = vs Day 1, baseline J Am Coll Cardiol 2011;57:

Results: Tubular markers Diuretic withdrawal J Am Coll Cardiol 2011;57:

Results: Tubular markers Diuretic Reinitiation Median and IQRs are presented. * P < 0.05 vs Day 4, 0 hours J Am Coll Cardiol 2011;57:

Results: Tubular markers Diuretic Reinitiation J Am Coll Cardiol 2011;57:

Results: Tubular markers Absolute Changes Diuretic WithdrawalDiuretic Reinitiation J Am Coll Cardiol 2011;57:

Results: correlations  No significant correlation between changes in Natriuretic Peptides and changes in tubular damage markers  No significant correlations between changes in tubular markers and changes in serum creatinine J Am Coll Cardiol 2011;57:

Results: findings  Diuretic withdrawal lead to:  an increase in ANP apparent after 4 hours  an increase in BNP apparent at day 4  no significant alterations in serum creatinine  an increase in urinary KIM-1, apparant after 8 hours, which was sustained through day 4  an increase in urinary NAG, apparent at day 3  no change in either serum or urinary NGAL levels J Am Coll Cardiol 2011;57:

Results: findings  Diuretic reinitiation lead to:  no decrease in ANP, but further increase  a decrease in BNP to baseline levels  no change in serum creatinine  a decrease in urinary KIM-1, apparant after 4 hours, which was sustained through day 7  a decrease in urinary NAG, apparent after 8 hours, and which was sustained through day 7  no change in either serum or urinary NGAL levels J Am Coll Cardiol 2011;57:

Conclusion  Diuretic withdrawal leads to increased markers of volume overload and this was paralleled by an increase in urinary levels of markers of tubular damage, especially KIM-1 and NAG  Reinitiation of diuretics leads to reduction of both urinary KIM-1 and NGAL  There was no effect of diuretic manipulation on NGAL levels J Am Coll Cardiol 2011;57:

Discussion  Modulation of volume (overload), even in HF patients with a presumed euvolemic state caused changes in tubular damage markers, but not serum creatinine  These markers are much more sensitive to small changes in glomerular and tubular function/integrity, and may therefore serve as early and specific markers of impaired renal function.  On the other hand, elevated tubular markers also indicate tubulo-interstitial damage. J Am Coll Cardiol 2011;57:

Discussion How does diuretic therapy influence (renal) tubular function? 2 Hypotheses:  (renal) Congestion causes tubular damage and renal interstitial fibrosis in heart failue. Diuretics directly improve congestion, therefore tubular function  Diuretic therapy decreases workload of the proximal tubule (less salt retained), which induces favourable conditions: less oxygen consumption, decreased renal hypoxia. J Am Coll Cardiol 2011;57:

Discussion Future studies are needed to:  Investigate placebo-controlled effects of diuretics on renal function and outcome  Identify high risk individuals for the development of WRF, using specific new tubular markers, such as KIM-1 / NAG/NGAL  Investigate the ability of these new markers to monitor and guide therapy in heart failure, especially diuretic therapy J Am Coll Cardiol 2011;57:

Acknowledgments Birmingham, UK: Dr. R MacFadyen Dr. JMNK Chuen Dr. GYH Lip Dr. L Fransisco Groningen, NL: Prof. dr. DJ van Veldhuisen Prof. dr. HL Hillege Prof. dr. G Navis Prof. dr. AA Voors W. Van Oeveren J Am Coll Cardiol 2011;57: